After that, researchers developed a variety of biological agents which targeted inflammatory factors in the pathogenesis of psoriasis, such as ixekizumab (IL‐17 inhibitors) and guselkumab (IL‐23 inhibitors) have been invented, they were reported to play a core role in targeting the IL‐23/Th17 axis.5 Here, IL17A is linked to psoriasis.